These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

701 related articles for article (PubMed ID: 27866851)

  • 1. Inhibition of the Glycolytic Activator PFKFB3 in Endothelium Induces Tumor Vessel Normalization, Impairs Metastasis, and Improves Chemotherapy.
    Cantelmo AR; Conradi LC; Brajic A; Goveia J; Kalucka J; Pircher A; Chaturvedi P; Hol J; Thienpont B; Teuwen LA; Schoors S; Boeckx B; Vriens J; Kuchnio A; Veys K; Cruys B; Finotto L; Treps L; Stav-Noraas TE; Bifari F; Stapor P; Decimo I; Kampen K; De Bock K; Haraldsen G; Schoonjans L; Rabelink T; Eelen G; Ghesquière B; Rehman J; Lambrechts D; Malik AB; Dewerchin M; Carmeliet P
    Cancer Cell; 2016 Dec; 30(6):968-985. PubMed ID: 27866851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor vessel disintegration by maximum tolerable PFKFB3 blockade.
    Conradi LC; Brajic A; Cantelmo AR; Bouché A; Kalucka J; Pircher A; Brüning U; Teuwen LA; Vinckier S; Ghesquière B; Dewerchin M; Carmeliet P
    Angiogenesis; 2017 Nov; 20(4):599-613. PubMed ID: 28875379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of glycolytic activator PFKFB3 suppresses tumor growth and induces tumor vessel normalization in hepatocellular carcinoma.
    Matsumoto K; Noda T; Kobayashi S; Sakano Y; Yokota Y; Iwagami Y; Yamada D; Tomimaru Y; Akita H; Gotoh K; Takeda Y; Tanemura M; Umeshita K; Doki Y; Eguchi H
    Cancer Lett; 2021 Mar; 500():29-40. PubMed ID: 33307155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual inhibition of PFKFB3 and VEGF normalizes tumor vasculature, reduces lactate production, and improves chemotherapy in glioblastoma: insights from protein expression profiling and MRI.
    Zhang J; Xue W; Xu K; Yi L; Guo Y; Xie T; Tong H; Zhou B; Wang S; Li Q; Liu H; Chen X; Fang J; Zhang W
    Theranostics; 2020; 10(16):7245-7259. PubMed ID: 32641990
    [No Abstract]   [Full Text] [Related]  

  • 5. Glycolytic regulation of cell rearrangement in angiogenesis.
    Cruys B; Wong BW; Kuchnio A; Verdegem D; Cantelmo AR; Conradi LC; Vandekeere S; Bouché A; Cornelissen I; Vinckier S; Merks RM; Dejana E; Gerhardt H; Dewerchin M; Bentley K; Carmeliet P
    Nat Commun; 2016 Jul; 7():12240. PubMed ID: 27436424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphotoxin-α promotes tumor angiogenesis in HNSCC by modulating glycolysis in a PFKFB3-dependent manner.
    Yang JG; Wang WM; Xia HF; Yu ZL; Li HM; Ren JG; Chen G; Wang BK; Jia J; Zhang W; Zhao YF
    Int J Cancer; 2019 Sep; 145(5):1358-1370. PubMed ID: 30785217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis.
    Schoors S; De Bock K; Cantelmo AR; Georgiadou M; Ghesquière B; Cauwenberghs S; Kuchnio A; Wong BW; Quaegebeur A; Goveia J; Bifari F; Wang X; Blanco R; Tembuyser B; Cornelissen I; Bouché A; Vinckier S; Diaz-Moralli S; Gerhardt H; Telang S; Cascante M; Chesney J; Dewerchin M; Carmeliet P
    Cell Metab; 2014 Jan; 19(1):37-48. PubMed ID: 24332967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A high-throughput screening campaign against PFKFB3 identified potential inhibitors with novel scaffolds.
    Li J; Zhou Y; Eelen G; Zhou QT; Feng WB; Labroska V; Ma FF; Lu HP; Dewerchin M; Carmeliet P; Wang MW; Yang DH
    Acta Pharmacol Sin; 2023 Mar; 44(3):680-692. PubMed ID: 36114272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Glycolytic Enzyme PFKFB3 Is Involved in Estrogen-Mediated Angiogenesis via GPER1.
    Trenti A; Tedesco S; Boscaro C; Ferri N; Cignarella A; Trevisi L; Bolego C
    J Pharmacol Exp Ther; 2017 Jun; 361(3):398-407. PubMed ID: 28348059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ablation of endothelial Pfkfb3 protects mice from acute lung injury in LPS-induced endotoxemia.
    Wang L; Cao Y; Gorshkov B; Zhou Y; Yang Q; Xu J; Ma Q; Zhang X; Wang J; Mao X; Zeng X; Su Y; Verin AD; Hong M; Liu Z; Huo Y
    Pharmacol Res; 2019 Aug; 146():104292. PubMed ID: 31167111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting PFKFB3 in the Endothelium for Cancer Therapy.
    Yang Q; Hou P
    Trends Mol Med; 2017 Mar; 23(3):197-200. PubMed ID: 28173976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperglycolysis in endothelial cells drives endothelial injury and microvascular alterations in peritoneal dialysis.
    Si Z; Su W; Zhou Z; Li J; Su C; Zhang Y; Hu Z; Huang Z; Zhou H; Cong A; Zhou Z; Cao W
    Clin Transl Med; 2023 Dec; 13(12):e1498. PubMed ID: 38037461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of PFKFB3 induces cell death and synergistically enhances chemosensitivity in endometrial cancer.
    Xiao Y; Jin L; Deng C; Guan Y; Kalogera E; Ray U; Thirusangu P; Staub J; Sarkar Bhattacharya S; Xu H; Fang X; Shridhar V
    Oncogene; 2021 Feb; 40(8):1409-1424. PubMed ID: 33420377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of PFKFB3-driven glycolysis in vessel sprouting.
    De Bock K; Georgiadou M; Schoors S; Kuchnio A; Wong BW; Cantelmo AR; Quaegebeur A; Ghesquière B; Cauwenberghs S; Eelen G; Phng LK; Betz I; Tembuyser B; Brepoels K; Welti J; Geudens I; Segura I; Cruys B; Bifari F; Decimo I; Blanco R; Wyns S; Vangindertael J; Rocha S; Collins RT; Munck S; Daelemans D; Imamura H; Devlieger R; Rider M; Van Veldhoven PP; Schuit F; Bartrons R; Hofkens J; Fraisl P; Telang S; Deberardinis RJ; Schoonjans L; Vinckier S; Chesney J; Gerhardt H; Dewerchin M; Carmeliet P
    Cell; 2013 Aug; 154(3):651-63. PubMed ID: 23911327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
    Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
    Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro angiogenesis inhibition with selective compounds targeting the key glycolytic enzyme PFKFB3.
    Abdali A; Baci D; Damiani I; Belloni F; De Dominicis C; Gelmi ML; Corsini A; Bellosta S
    Pharmacol Res; 2021 Jun; 168():105592. PubMed ID: 33813027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The PFKFB3 Inhibitor AZ67 Inhibits Angiogenesis Independently of Glycolysis Inhibition.
    Emini Veseli B; Van Wielendaele P; Delibegovic M; Martinet W; De Meyer GRY
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase-3 is required for transforming growth factor β1-enhanced invasion of Panc1 cells in vitro.
    Yalcin A; Solakoglu TH; Ozcan SC; Guzel S; Peker S; Celikler S; Balaban BD; Sevinc E; Gurpinar Y; Chesney JA
    Biochem Biophys Res Commun; 2017 Mar; 484(3):687-693. PubMed ID: 28161638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancer.
    O'Neal J; Clem A; Reynolds L; Dougherty S; Imbert-Fernandez Y; Telang S; Chesney J; Clem BF
    Breast Cancer Res Treat; 2016 Nov; 160(1):29-40. PubMed ID: 27613609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incomplete and transitory decrease of glycolysis: a new paradigm for anti-angiogenic therapy?
    Schoors S; Cantelmo AR; Georgiadou M; Stapor P; Wang X; Quaegebeur A; Cauwenberghs S; Wong BW; Bifari F; Decimo I; Schoonjans L; De Bock K; Dewerchin M; Carmeliet P
    Cell Cycle; 2014; 13(1):16-22. PubMed ID: 24335389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.